|
1) Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of the vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19: 429-35
|
|
|
|
2) Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004; 113: 561-8
|
|
|
|
|
|
3) Chang Q, Hoefs S, van der Kemp AW. The β-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science. 2005; 310: 490
|
|
|
|
|
|
4) Tsujikawa H, Kurotaki Y, Fujimori T, et al. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol. 2003; 17: 2393-403
|
|
|
|
|
|
5) Kuro-o M. Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens. 2006; 15: 437-41
|
|
|
|
|
|
6) Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006; 444: 770-4
|
|
|
|
|
|
7) Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res. 2004; 95: 560-7
|
|
|
|
|
|
8) Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 2006; 69: 33-43
|
|
|
|
|
|
9) Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000; 87: E10-7
|
|
|
|
|
|
10) Mizobuchi M, Ogata H, Hatamura I, et al. Up-regulation of Cbfa1 and Pit-1 in calcified artery of uraemic rats with severe hyperphosphataemia and secondary hyperparathyroidism. Nephrol Dial Transplant. 2006; 21: 911-6
|
|
|
|
|
|
11) Moe SM, Reslerova M, Ketteler M, et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int. 2005; 67: 2295-304
|
|
|
|
|
|
12) Jono S, Shioi A, Ikari Y, et al. Vascular calcification in chronic kidney disease. J Bone Miner Metab. 2006; 24: 176-81
|
|
|
|
|
13) Cozzolino M, Brancaccio D, Gallieni M, et al. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int. 2005; 68: 429-36
|
|
|
|
|
|
14) Schwarz S, Trivedi BK, Kalantar-zadeh K. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol. 2006; 1: 825-31
|
|
|
|
|
|
15) Rubel JR, Milford EL. The relationship between serum calcium and phosphate levels and cardiac valvular procedures in the hemodialysis popula-tion. Am J Kidney Dis. 2003; 41: 411-21
|
|
|
|
|
|
16) Shigematsu T, Kono T, Satoh K, et al. Phosphate overload accelerates vascular calcium deposition in end-stage renal disease patients. Nephrol Dial Transplant. 2003; 18 Suppl 3: iii86-9
|
|
|
|
|
|
17) Noordzij M, Korevaar JC, Bos WJ, et al. Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients. Nephrol Dial Transplant. 2006; 21: 2513-20
|
|
|
|
|
|
18) Ganesh SK, Stack AG, Levin NW, et al. Associa-tion of elevated serum PO(4), Ca×PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001; 12: 2131-8
|
|
|
|
|
|
19) Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in main-tenance hemodialysis. J Am Soc Nephrol. 2004; 15: 2208-18
|
|
|
|
|
|
20) Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006; 70: 771-80
|
|
|
|
|
|
21) Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005; 67: 1179-87
|
|
|
|
|
|
22) Matsuoka M, Iseki K, Tamashir M, et al. Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol. 2004; 8: 54-8
|
|
|
|
|
|
23) Tanaka M, Yamazaki S, Hayashino Y, et al. Hypercalcaemia is associated with poor mental health in haemodialysis patients: results from Japan DOPPS. Nephrol Dial Transplant. 2007; 22: 1658-64
|
|
|
|
|
|
24) Noordzij M, Korevaar JC, Boeschoten EW, et al. Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group. The kidney disease outcomes quality initiative (K/DOQI) guideline for bone metabolism and disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis. 2005; 46: 925-32
|
|
|
|
|
|
25) Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62: 245-52
|
|
|
|
|
|
26) Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005; 68: 1815-24
|
|
|
|
|
|
27) Cardus A, Panizo S, Parisi E, et al. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res. 2007; 22: 860-6
|
|
|
|
|
|
28) Mizobuchi M, Finch JL, Martin DR, et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int. 2007; 72: 709-15
|
|
|
|
|
|
29) Wolisi GO, Moe SM. The role of vitamin D in vascular calcification in chronic kidney disease. Semin Dial. 2005; 18: 307-14
|
|
|
|
|
|
30) Ogata H, Koiwa F, Ito H, et al. Therapeutic strategies for secondary hyperparathyroidism in dialysis patients. Ther Apher Dial. 2006; 10: 355-63
|
|
|
|
|
|
31) Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005; 67: 760-71
|
|
|
|
|
|
32) Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004; 350: 1516-25
|
|
|
|
|
|
33) Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardio-vascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005; 6: 1793-800
|
|
|
|
|